Fig. 3From: A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumoursOverall Survival 3a Overall survival in the overall patient population 3b Overall survival in the breast cancer subgroup 3c Overall survival in the lung cancer subgroup 3d Overall survival in the other cancers subgroupBack to article page